Company intelligence / Profile preview
Canyon Pharmaceuticals
Columbia, Maryland, United Statescanyonpharma.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Canyon Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on developing and commercializing therapies targeting thrombosis, inflammation, and cancer. Its lead product is a recombinant anticoagulant in the class of direct thrombin inhibitors—Desirudin—which has been evaluated in multiple clinical trials for thrombosis prevention as an alternative to heparin-based anticoagulation. The company’s main indication focus includes VTE prophylaxis[1][2][3].
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecules (notably direct thrombin inhibitors such as Desirudin)[3][2]
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Canyon Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Canyon Pharmaceuticals.